Conditions: Major Depressive Disorder Anxiety
Keywords: schizophrenia Major depressive disorder Anxiety Symptoms Mental Disorders Psychotic Disorders emotional withdrawal antipsychotic
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 37
Healthy volunteers: no

Brief summary:
The purpose of this study is to investigate the efficacy and safety of flexibly dosed adjunctive brexpiprazole treatment in subjects with major depressive disorder and anxiety symptoms, who are experiencing an inadequate selective serotonin reuptake inhibitor (SSRI)/serotonin norepinephrine reuptake inhibitor (SNRI) response.

Detailed description:

Arms:
arm 1: Up to 3 mg/day, once daily dose, tablets, orally

Interventions: intervention 1: Brexpiprazole
Intervention descriptions: intervention 1: Treatment (6 weeks) - Up to 3mg/day, once daily dose, tablets, orally

Protocol document: